- bluebird bio Trading Down 5.7 %
- Institutional Trading of bluebird bio
- bluebird bio Company Profile
- See Also
bluebird bio, Inc. (NASDAQ:BLUE – Get Rating) – Investment analysts at SVB Leerink lowered their FY2022 EPS estimates for bluebird bio in a research note issued on Wednesday, November 30th. SVB Leerink analyst M. Foroohar now forecasts that the biotechnology company will post earnings per share of ($4.68) for the year, down from their prior forecast of ($3.93). SVB Leerink has a “Market Perform” rating and a $10.00 price target on the stock. The consensus estimate for bluebird bio’s current full-year earnings is ($4.18) per share. SVB Leerink also issued estimates for bluebird bio’s Q4 2022 earnings at ($0.72) EPS.
BLUE has been the topic of several other research reports. Royal Bank of Canada cut their target price on bluebird bio to $8.00 and set a “sector perform” rating on the stock in a research report on Tuesday, November 8th. The Goldman Sachs Group increased their price target on bluebird bio from $2.00 to $3.00 and gave the stock a “sell” rating in a report on Friday, August 19th. Raymond James lifted their price objective on shares of bluebird bio from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Tuesday, September 20th. Finally, StockNews.com assumed coverage on shares of bluebird bio in a research report on Wednesday, October 12th. They set a “sell” rating on the stock. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, bluebird bio presently has a consensus rating of “Hold” and a consensus target price of $6.88.
bluebird bio Trading Down 5.7 %
Shares of bluebird bio stock opened at $8.01 on Monday. The business has a 50-day moving average price of $6.78 and a two-hundred day moving average price of $5.61. bluebird bio has a 1-year low of $2.87 and a 1-year high of $11.70. The company has a market cap of $664.11 million, a P/E ratio of -1.31 and a beta of 0.98.
Institutional Trading of bluebird bio
Hedge funds have recently bought and sold shares of the business. Metropolitan Life Insurance Co NY lifted its stake in shares of bluebird bio by 142.4% in the third quarter. Metropolitan Life Insurance Co NY now owns 4,671 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 2,744 shares in the last quarter. Amalgamated Bank bought a new stake in shares of bluebird bio during the first quarter worth about $39,000. PEAK6 Investments LLC acquired a new stake in shares of bluebird bio in the 2nd quarter worth about $41,000. US Bancorp DE lifted its position in bluebird bio by 82.9% in the 1st quarter. US Bancorp DE now owns 8,486 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 3,847 shares in the last quarter. Finally, Keybank National Association OH acquired a new position in bluebird bio during the 2nd quarter valued at about $42,000. Institutional investors and hedge funds own 78.25% of the company’s stock.